-
-
-
-
-
-
-
InnoCare drug meets primary goal in lupus trial for Zenas partner
-
-
-
-
-
-
-
Royalty Pharma provides up to $300 million to Zenas BioPharma for obexelimab
-
-
-
-
-
-
-
ZBIO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action
-
-
-
-
-
-
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
-
-
-
-
-
-
-
ZBIO Investors Have the Opportunity to Lead the Zenas BioPharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
-
-
-
-
-
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
-
-
-
-
-
-
-
ZBIO DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

